hydroxyurea has been researched along with Benign Neoplasms in 134 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In myeloproliferative neoplasms (MPNs), the immature platelet fraction (IPF) rises due to enhanced platelet turnover, and this has been thought to reduce the efficacy of aspirin." | 5.91 | Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter? ( Akay, OM; Erdoğan Özünal, I; Göktürk, A; Kaya, AH; Koçak Göktürk, I; Öztürk, E; Yılmaz, G, 2023) |
| " Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality." | 2.75 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. ( Armstrong, FD; Ataga, K; Ballas, SK; Castro, O; DeCastro, L; Kutlar, A; McCarthy, WF; Smith, W; Steinberg, MH; Swerdlow, P; Waclawiw, MA, 2010) |
| "Hydroxyurea (HU) is a water-soluble antiproliferative agent used for decades in neoplastic and nonneoplastic conditions." | 2.72 | Mechanisms of Hydroxyurea-Induced Cellular Senescence: An Oxidative Stress Connection? ( Čokić, V; Kapor, S; Santibanez, JF, 2021) |
| "Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival." | 2.72 | Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. ( Dertinger, SD; Ware, RE, 2021) |
| "The sequencing of cancer genomes reveals multiple point mutations that compromise the activity of POLD1, the DNA Pol δ catalytic subunit, whereas the loci encoding the accessory subunits POLD2 and POLD3 are amplified in a very high proportion of human tumors." | 2.72 | Underappreciated Roles of DNA Polymerase δ in Replication Stress Survival. ( Cheblal, A; Fuchs, J; Gasser, SM, 2021) |
| " hydroxyurea (HU) in combination with i." | 2.70 | Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ( Garcia, AA; Jeffers, S; Koda, RT; Muggia, FM; Pujari, M; Silberman, H; Spears, CP, 2001) |
| "Despite the widespread usage of hydroxyurea in the treatment of both malignant and nonmalignant diseases and a recent expansion in the recognition of its potential therapeutic applications, there have been few detailed studies of hydroxyurea's pharmacokinetic (PK) behavior and oral bioavailability." | 2.69 | A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ( Eckardt, JR; Hilsenbeck, SG; Hodges, S; Kuhn, JG; Rinaldi, DA; Rodriguez, GI; Rowinsky, EK; Thurman, A; Von Hoff, DD; Weiss, GR, 1998) |
| "A group of 18 patients with advanced cancer were entered on a phase I study of a 120-h continuous intravenous infusion of hydroxyurea." | 2.68 | Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ( Ahn, CW; Akman, SA; Carroll, M; Chow, W; Coluzzi, P; Doroshow, JH; Hamasaki, V; Leong, LA; Margolin, KA; Morgan, RJ; Newman, EM; Raschko, JW; Shibata, S; Somlo, G; Tetef, M; Yen, Y, 1997) |
| " On the basis of the minimal value of the objective function (MVOF) and prior knowledge of the disposition of HU in animals and man, the data were best described by a one-compartment pharmacokinetic model with parallel Michaelis-Menten metabolism and first-order renal excretion." | 2.68 | Population pharmacokinetics of hydroxyurea in cancer patients. ( Gwilt, PR; Smith, DC; Tracewell, WG; Trump, DL; Vaughan, WP, 1995) |
| "Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil (5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days." | 2.67 | Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial. ( Anderson, N; Bern, M; Coco, F; Gonsalves, L; Lokich, J; Moore, C; Zipoli, T, 1991) |
| "Hydroxyurea and etoposide were antagonistic at low doses at which the survival fraction was greater than 0." | 2.66 | Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. ( Ratain, MJ; Schilsky, RL; Senekjian, EK; Simon, T; Vogelzang, NJ; Wojack, BR, 1988) |
| "Hydroxyurea (HU) is a simple organic compound currently used as a cancer chemotherapeutic agent." | 2.48 | Hydroxyurea: a key player in cancer chemotherapy. ( Kaushik, D; Madaan, K; Verma, T, 2012) |
| "Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer." | 2.45 | Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. ( Bujak, M; Saban, N, 2009) |
| " Hydroxyurea is responsible for some peculiar cutaneous side effects (ulcerations, pseudo-dermatomyositis), perhaps due to long-term administration of the drug." | 2.42 | Mucocutaneous side effects of antineoplastic chemotherapy. ( Bessis, D; Dereure, O; Guillot, B, 2004) |
| "Tumor cell resistance to cancer chemotherapeutic agents is a well-recognized problem for clinicians." | 2.39 | Use of hydroxyurea to alter drug resistance of human tumor cells. ( Van den Berg, C; Von Hoff, DD, 1995) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| "Prepubertal patients with childhood cancer or hematological disorders were more likely to have significantly reduced spermatogonial quantity compared to healthy controls (48." | 1.91 | Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort. ( Feijen, EAM; Goossens, E; Jahnukainen, K; Kremer, LMC; Masliukaite, I; Meissner, A; Ntemou, E; Repping, S; Soufan, AT; van de Wetering, M; van Pelt, AMM, 2023) |
| "In myeloproliferative neoplasms (MPNs), the immature platelet fraction (IPF) rises due to enhanced platelet turnover, and this has been thought to reduce the efficacy of aspirin." | 1.91 | Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter? ( Akay, OM; Erdoğan Özünal, I; Göktürk, A; Kaya, AH; Koçak Göktürk, I; Öztürk, E; Yılmaz, G, 2023) |
| "A major driver of cancer chromosomal instability is replication stress, the slowing or stalling of DNA replication." | 1.72 | Replication stress generates distinctive landscapes of DNA copy number alterations and chromosome scale losses. ( Bakker, B; Boemo, MA; De Angelis, S; Foijer, F; Johnson, SC; Maniati, E; Mazzagatti, A; McClelland, SE; Shaikh, N; Spierings, DCJ; Wang, J; Wardenaar, R, 2022) |
| "Only pediatrics patients with beta thalassemia major and those who were on chemotherapy treatment and post-transplant patient were included in this study." | 1.62 | Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance. ( Al-Quteimat, O; Ali, K; Ansari, SH; Jahan, N; Malhi, SM; Naseem, R; Shamsi, TS; Wajdi, M, 2021) |
| "To evaluate the cancer-targeting ability of rhamnose moiety, the rhamnose-conjugated fluorescence dye rhodamine B (Rha-RhB) was constructed." | 1.51 | Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy. ( Jin, L; Li, Y; Liu, X; Lu, L; Qu, J; Xiao, M; Xu, L; Yin, Z, 2019) |
| "FTs are considered to be enriched in cancer stem-like cells (CS-LCs)." | 1.51 | Chemoresistance of cancer floating cells is independent of their ability to form 3D structures: Implications for anticancer drug screening. ( Azad, N; Iyer, AKV; Kaushik, V; Way, LF; Yakisich, JS, 2019) |
| "Boys facing cancer and cytotoxic therapies are regarded as the major group who will benefit from novel fertility preservation techniques." | 1.48 | Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy. ( Albalushi, H; Alves-Lopes, JP; Bjarnason, R; Henningsohn, L; Jahnukainen, K; Keros, V; Kurek, M; Langenskiöld, C; Mitchell, RT; Norén Nyström, U; Petersen, C; Reda, A; Romerius, P; Söder, O; Stukenborg, JB; Sundin, M; Töhönen, V; Vogt, H, 2018) |
| "Irofulven has displayed significant antitumor activity in various clinical trials but displayed a limited therapeutic index." | 1.43 | Hydroxyurea derivatives of irofulven with improved antitumor efficacy. ( Estes, LA; Kashinatham, A; Kelner, MJ; McMorris, TC; Staake, MD, 2016) |
| "Conversely, cancer cells with abundant endogenous intracellular dNTPs or treated with dNTP precursors were less responsive to autophagy induction by rapamycin, suggesting that autophagy and dNTP pool levels are regulated through a negative feedback loop." | 1.40 | Reciprocal regulation of autophagy and dNTP pools in human cancer cells. ( Ann, DK; Chen, L; Chen, W; Chen, YR; Hu, S; Kuo, ML; Tang, M; Yang, L; Yen, Y; Zhang, K; Zhang, L; Zhou, B, 2014) |
| "In mouse xenograft models of human cancer, COH29 treatment reduced tumor growth compared with vehicle." | 1.39 | A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. ( Gaur, S; Horne, D; Hu, S; Hu, W; Smith, DL; Su, L; Synold, TW; Wu, J; Yen, Y; Yip, ML; Yuan, YC; Zhou, B, 2013) |
| "Correlations between the degree of malignancy, patient prognostic index and HMGA levels have been firmly established." | 1.35 | HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. ( Bao, Q; Dröge, P; Goodman, SD; Henderson, D; Klonisch, T; Li, O; Peter, S; Sathiyanathan, P; Summer, H; Zhan, L, 2009) |
| "Hydroxyurea (HU) is a chemotherapeutic agent commonly used for various malignancies and hematological disorders, including chronic myelogenous leukemia and sickle cell anemia." | 1.35 | Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres. ( Deng, Z; Lieberman, PM; Snyder, AR; Zhou, J, 2009) |
| "Our results identify a class of anticancer agents that integrate ER stress response with an epigenetic mechanism to induce cell death." | 1.35 | ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. ( Chen, W; Hai, T; Mora-Jensen, H; Perez-Galan, P; Ron, D; Trenkle, W; Wang, Q; Weniger, MA; Wiestner, A; Wolford, C; Ye, Y, 2009) |
| "The median age at malignancy diagnosis was 34 years (range, 14 months-62 years)." | 1.32 | Malignancy in patients with sickle cell disease. ( Schultz, WH; Ware, RE, 2003) |
| "Most nucleoside-derived anticancer drugs are taken up by the high-affinity Na-dependent nucleoside transporter CNT1." | 1.31 | Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. ( Casado, FJ; Pastor-Anglada, M; Valdés, R, 2002) |
| "STI571 is a novel anticancer agent that selectively inhibits the BCR/ABL tyrosine kinase." | 1.31 | In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. ( Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001) |
| "Use of this test in cancer patients undergoing either chemotherapy or radiation therapy revealed evidence of early negative B12 balance that in some instances was induced by the treatment itself." | 1.29 | New assay for the rapid determination of plasma holotranscobalamin II levels: preliminary evaluation in cancer patients. ( Amin, J; Flener, V; Ramos, M; Tisman, G; Vanyo, L; Vu, T, 1993) |
| "eight cancer patients treated with radiotherapy and/or chemotherapy (r/c cancer patients) and six chromium workers." | 1.28 | Induction of DNA-repair synthesis (UDS) in rat pleural mesothelial cells by urine of subjects exposed to genotoxic agents. ( Brochard, P; Jaurand, MC; Levy, F; Pilliere, F; Renier, A, 1992) |
| "All patients had refractory solid tumors." | 1.28 | Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model. ( Albain, KS; Erickson, LC; Fisher, RI; Stiff, PJ; Swinnen, LJ, 1990) |
| "Hydroxyurea was administered by means of two schedules designed to provide continuous 72-hour exposure of tumor cells to therapeutic drug levels." | 1.26 | Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. ( Belt, RJ; Haas, CD; Kennedy, J; Taylor, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (44.78) | 18.7374 |
| 1990's | 17 (12.69) | 18.2507 |
| 2000's | 21 (15.67) | 29.6817 |
| 2010's | 22 (16.42) | 24.3611 |
| 2020's | 14 (10.45) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, MA | 1 |
| Marques, S | 1 |
| Vullo, D | 1 |
| Innocenti, A | 1 |
| Scozzafava, A | 1 |
| Supuran, CT | 1 |
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Staake, MD | 1 |
| Kashinatham, A | 1 |
| McMorris, TC | 1 |
| Estes, LA | 1 |
| Kelner, MJ | 1 |
| Kapor, S | 1 |
| Čokić, V | 1 |
| Santibanez, JF | 1 |
| Sabbagh, S | 1 |
| Jarrah, K | 1 |
| Bou-Fakhredin, R | 1 |
| Saadeh, D | 1 |
| Taher, AT | 1 |
| Shaikh, N | 1 |
| Mazzagatti, A | 1 |
| De Angelis, S | 1 |
| Johnson, SC | 1 |
| Bakker, B | 1 |
| Spierings, DCJ | 1 |
| Wardenaar, R | 1 |
| Maniati, E | 1 |
| Wang, J | 1 |
| Boemo, MA | 1 |
| Foijer, F | 1 |
| McClelland, SE | 1 |
| Masliukaite, I | 1 |
| Ntemou, E | 1 |
| Feijen, EAM | 1 |
| van de Wetering, M | 1 |
| Meissner, A | 1 |
| Soufan, AT | 1 |
| Repping, S | 1 |
| Kremer, LMC | 1 |
| Jahnukainen, K | 2 |
| Goossens, E | 1 |
| van Pelt, AMM | 1 |
| Koçak Göktürk, I | 1 |
| Erdoğan Özünal, I | 1 |
| Göktürk, A | 1 |
| Kaya, AH | 1 |
| Yılmaz, G | 1 |
| Akay, OM | 1 |
| Öztürk, E | 1 |
| Massarenti, L | 1 |
| Knudsen, TA | 1 |
| Enevold, C | 1 |
| Skov, V | 1 |
| Kjaer, L | 1 |
| Larsen, MK | 1 |
| Larsen, TS | 1 |
| Hansen, DL | 1 |
| Hasselbalch, HC | 1 |
| Nielsen, CH | 1 |
| Jaiswal, RK | 1 |
| Lei, KH | 1 |
| Chastain, M | 1 |
| Wang, Y | 2 |
| Shiva, O | 1 |
| Li, S | 1 |
| You, Z | 1 |
| Chi, P | 1 |
| Chai, W | 1 |
| Xu, L | 1 |
| Liu, X | 1 |
| Yin, Z | 1 |
| Jin, L | 1 |
| Lu, L | 1 |
| Qu, J | 1 |
| Xiao, M | 1 |
| Kiweler, N | 2 |
| Wünsch, D | 1 |
| Wirth, M | 1 |
| Mahendrarajah, N | 2 |
| Schneider, G | 2 |
| Stauber, RH | 1 |
| Brenner, W | 1 |
| Butter, F | 1 |
| Krämer, OH | 2 |
| Ali, K | 1 |
| Al-Quteimat, O | 1 |
| Naseem, R | 1 |
| Malhi, SM | 1 |
| Wajdi, M | 1 |
| Jahan, N | 1 |
| Ansari, SH | 1 |
| Shamsi, TS | 1 |
| Tang, L | 1 |
| Wang, Z | 1 |
| Mu, Q | 1 |
| Yu, Z | 1 |
| Jacobson, O | 1 |
| Li, L | 1 |
| Yang, W | 1 |
| Huang, C | 1 |
| Kang, F | 1 |
| Fan, W | 1 |
| Ma, Y | 1 |
| Wang, M | 1 |
| Zhou, Z | 1 |
| Chen, X | 1 |
| Ware, RE | 2 |
| Dertinger, SD | 1 |
| Fuchs, J | 1 |
| Cheblal, A | 1 |
| Gasser, SM | 1 |
| Bader, SB | 1 |
| Ma, TS | 1 |
| Simpson, CJ | 1 |
| Liang, J | 1 |
| Maezono, SEB | 1 |
| Olcina, MM | 1 |
| Buffa, FM | 1 |
| Hammond, EM | 1 |
| Contreras Castillo, S | 1 |
| Montibus, B | 1 |
| Rocha, A | 1 |
| Duke, W | 1 |
| von Meyenn, F | 1 |
| McLornan, D | 1 |
| Harrison, C | 1 |
| Mullally, A | 2 |
| Schulz, R | 1 |
| Oakey, RJ | 1 |
| Singh, DK | 1 |
| Pandita, RK | 1 |
| Singh, M | 1 |
| Chakraborty, S | 1 |
| Hambarde, S | 1 |
| Ramnarain, D | 1 |
| Charaka, V | 1 |
| Ahmed, KM | 1 |
| Hunt, CR | 1 |
| Pandita, TK | 1 |
| Stukenborg, JB | 1 |
| Alves-Lopes, JP | 1 |
| Kurek, M | 1 |
| Albalushi, H | 1 |
| Reda, A | 1 |
| Keros, V | 1 |
| Töhönen, V | 1 |
| Bjarnason, R | 1 |
| Romerius, P | 1 |
| Sundin, M | 1 |
| Norén Nyström, U | 1 |
| Langenskiöld, C | 1 |
| Vogt, H | 1 |
| Henningsohn, L | 1 |
| Mitchell, RT | 1 |
| Söder, O | 1 |
| Petersen, C | 1 |
| Kaushik, V | 1 |
| Yakisich, JS | 1 |
| Way, LF | 1 |
| Azad, N | 1 |
| Iyer, AKV | 1 |
| Islam, W | 1 |
| Fang, J | 1 |
| Imamura, T | 1 |
| Etrych, T | 1 |
| Subr, V | 1 |
| Ulbrich, K | 1 |
| Maeda, H | 1 |
| Pathak, PK | 1 |
| Kumar, A | 1 |
| Prasad, BB | 1 |
| Díaz-Talavera, A | 1 |
| Calvo, PA | 1 |
| González-Acosta, D | 1 |
| Díaz, M | 1 |
| Sastre-Moreno, G | 1 |
| Blanco-Franco, L | 1 |
| Guerra, S | 1 |
| Martínez-Jiménez, MI | 1 |
| Méndez, J | 1 |
| Blanco, L | 1 |
| Natarajan, S | 1 |
| Hombach-Klonisch, S | 1 |
| Dröge, P | 2 |
| Klonisch, T | 2 |
| Zhou, B | 2 |
| Su, L | 1 |
| Hu, S | 2 |
| Hu, W | 1 |
| Yip, ML | 1 |
| Wu, J | 1 |
| Gaur, S | 1 |
| Smith, DL | 1 |
| Yuan, YC | 1 |
| Synold, TW | 1 |
| Horne, D | 1 |
| Yen, Y | 4 |
| Chen, W | 2 |
| Zhang, K | 1 |
| Kuo, ML | 1 |
| Chen, L | 1 |
| Tang, M | 1 |
| Chen, YR | 1 |
| Yang, L | 1 |
| Ann, DK | 1 |
| Wadhwa, P | 1 |
| Jain, P | 1 |
| Jadhav, HR | 1 |
| Chen, E | 1 |
| Ahn, JS | 1 |
| Sykes, DB | 1 |
| Breyfogle, LJ | 1 |
| Godfrey, AL | 1 |
| Nangalia, J | 1 |
| Ko, A | 1 |
| DeAngelo, DJ | 1 |
| Green, AR | 1 |
| Li, V | 1 |
| Langan, TJ | 1 |
| Rodgers, KR | 1 |
| Chou, RC | 1 |
| Iman, M | 1 |
| Khansefid, Z | 1 |
| Davood, A | 1 |
| Schäfer, C | 1 |
| Göder, A | 1 |
| Beyer, M | 1 |
| Rauch, A | 1 |
| Nikolova, T | 1 |
| Stojanovic, N | 1 |
| Wieczorek, M | 1 |
| Reich, TR | 1 |
| Tomicic, MT | 1 |
| Linnebacher, M | 1 |
| Sonnemann, J | 1 |
| Dietrich, S | 1 |
| Sellmer, A | 1 |
| Mahboobi, S | 1 |
| Heinzel, T | 1 |
| Wang, Q | 1 |
| Mora-Jensen, H | 1 |
| Weniger, MA | 1 |
| Perez-Galan, P | 1 |
| Wolford, C | 1 |
| Hai, T | 1 |
| Ron, D | 1 |
| Trenkle, W | 1 |
| Wiestner, A | 1 |
| Ye, Y | 1 |
| Mijatovic, T | 1 |
| Jungwirth, U | 1 |
| Heffeter, P | 1 |
| Hoda, MA | 1 |
| Dornetshuber, R | 1 |
| Kiss, R | 1 |
| Berger, W | 1 |
| Saban, N | 1 |
| Bujak, M | 1 |
| Snyder, AR | 1 |
| Zhou, J | 1 |
| Deng, Z | 1 |
| Lieberman, PM | 1 |
| Summer, H | 1 |
| Li, O | 1 |
| Bao, Q | 1 |
| Zhan, L | 1 |
| Peter, S | 1 |
| Sathiyanathan, P | 1 |
| Henderson, D | 1 |
| Goodman, SD | 1 |
| Ranawaka, RR | 1 |
| Utani, K | 1 |
| Kohno, Y | 1 |
| Okamoto, A | 1 |
| Shimizu, N | 1 |
| Steinberg, MH | 1 |
| McCarthy, WF | 1 |
| Castro, O | 1 |
| Ballas, SK | 1 |
| Armstrong, FD | 1 |
| Smith, W | 1 |
| Ataga, K | 1 |
| Swerdlow, P | 1 |
| Kutlar, A | 1 |
| DeCastro, L | 1 |
| Waclawiw, MA | 1 |
| Kovacic, P | 1 |
| Končić, MZ | 1 |
| Barbarić, M | 1 |
| Perković, I | 1 |
| Zorc, B | 1 |
| Madaan, K | 1 |
| Kaushik, D | 1 |
| Verma, T | 1 |
| Valdés, R | 1 |
| Casado, FJ | 1 |
| Pastor-Anglada, M | 1 |
| Chow, W | 2 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Morgan, R | 1 |
| Raschko, J | 1 |
| Shibata, S | 2 |
| Somlo, G | 2 |
| Twardowski, P | 1 |
| Frankel, P | 1 |
| Longmate, J | 1 |
| Synold, T | 1 |
| Newman, EM | 2 |
| Lenz, HJ | 1 |
| Gandara, D | 1 |
| Doroshow, JH | 2 |
| Kast, RE | 1 |
| MOHLER, WC | 1 |
| ORIGENES, ML | 1 |
| BEATTY, EC | 1 |
| BRUBAKER, C | 1 |
| HAMMOND, D | 1 |
| HARTMANN, JR | 1 |
| SHORE, N | 1 |
| WILLIAMS, KO | 1 |
| SEARS, ME | 2 |
| FERNBACH, DJ | 1 |
| BLOEDOW, CE | 1 |
| HOWE, CD | 1 |
| SAMUELS, ML | 2 |
| DAVIS, P | 1 |
| KRAKOFF, IH | 1 |
| SAVEL, H | 1 |
| MURPHY, ML | 1 |
| LERNER, HJ | 3 |
| BECKLOFF, GL | 4 |
| COLE, DR | 1 |
| ROUSSELOT, LM | 1 |
| Bellier, B | 1 |
| Thomas-Vaslin, V | 1 |
| Saron, MF | 1 |
| Klatzmann, D | 1 |
| Schultz, WH | 1 |
| Guillot, B | 1 |
| Bessis, D | 1 |
| Dereure, O | 1 |
| Sorg, BL | 1 |
| Hull, WE | 1 |
| Kliem, HC | 1 |
| Mier, W | 1 |
| Wiessler, M | 1 |
| Durdux, C | 1 |
| Kim, SJ | 1 |
| Nam, YR | 1 |
| Shin, O | 1 |
| Choi, J | 1 |
| Lee, B | 1 |
| Chang, JW | 1 |
| Kwon, YK | 1 |
| Park, K | 1 |
| Lee, H | 1 |
| Lipshutz, H | 1 |
| Lomen, PL | 1 |
| Khilanani, P | 1 |
| Kessel, D | 1 |
| Steinherz, PG | 1 |
| Rosen, G | 1 |
| Ghavimi, F | 1 |
| Wollner, N | 1 |
| Miller, DR | 1 |
| Rupniak, HT | 1 |
| Whelan, RD | 1 |
| Hill, BT | 2 |
| Przybyszewski, WM | 1 |
| Malec, J | 1 |
| Levitt, DZ | 1 |
| Elkind, MM | 1 |
| Sinclair, WK | 1 |
| Belt, RJ | 1 |
| Haas, CD | 1 |
| Kennedy, J | 1 |
| Taylor, S | 1 |
| Tracewell, WG | 1 |
| Trump, DL | 2 |
| Vaughan, WP | 2 |
| Smith, DC | 2 |
| Gwilt, PR | 2 |
| Vu, T | 1 |
| Amin, J | 1 |
| Ramos, M | 1 |
| Flener, V | 1 |
| Vanyo, L | 1 |
| Tisman, G | 1 |
| Philip, PA | 2 |
| Kaklamanis, L | 1 |
| Carmichael, J | 1 |
| Tonkin, K | 1 |
| Morrison, H | 1 |
| Gatter, K | 1 |
| Harris, AL | 1 |
| Van den Berg, C | 1 |
| Von Hoff, DD | 2 |
| Wadler, S | 2 |
| Haynes, H | 2 |
| Schechner, R | 1 |
| Rozenblit, A | 1 |
| Wiernik, PH | 1 |
| Carroll, M | 1 |
| Akman, SA | 1 |
| Coluzzi, P | 1 |
| Hamasaki, V | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Raschko, JW | 1 |
| Tetef, M | 1 |
| Ahn, CW | 1 |
| Rodriguez, GI | 1 |
| Kuhn, JG | 1 |
| Weiss, GR | 1 |
| Hilsenbeck, SG | 1 |
| Eckardt, JR | 1 |
| Thurman, A | 1 |
| Rinaldi, DA | 1 |
| Hodges, S | 1 |
| Rowinsky, EK | 1 |
| Makower, D | 1 |
| Schwartz, EL | 1 |
| Navarra, P | 1 |
| Preziosi, P | 1 |
| Kano, Y | 1 |
| Akutsu, M | 1 |
| Tsunoda, S | 1 |
| Mano, H | 1 |
| Sato, Y | 1 |
| Honma, Y | 1 |
| Furukawa, Y | 1 |
| Garcia, AA | 1 |
| Muggia, FM | 1 |
| Spears, CP | 1 |
| Jeffers, S | 1 |
| Silberman, H | 1 |
| Pujari, M | 1 |
| Koda, RT | 1 |
| Villalón, L | 1 |
| Odriozola, J | 1 |
| Laraña, JG | 1 |
| Zamora, C | 1 |
| Pérez de Oteyza, J | 1 |
| Jodra, MH | 1 |
| López, J | 1 |
| Herrera, P | 1 |
| Roldán, E | 1 |
| Ramos, ML | 1 |
| Ramos, P | 1 |
| Navarro, JL | 1 |
| Price, LA | 1 |
| Calvert, AH | 1 |
| Shaw, HJ | 1 |
| Hughes, KB | 1 |
| DeWys, WD | 1 |
| Costanzi, JJ | 1 |
| Loukas, D | 1 |
| Gagliano, RG | 1 |
| Griffiths, C | 1 |
| Barranco, S | 1 |
| Bergstresser, PR | 1 |
| Schreiber, SH | 1 |
| Weinstein, GD | 1 |
| Klein, HO | 1 |
| Adler, D | 1 |
| Doering, M | 1 |
| Klein, PJ | 1 |
| Lennartz, KJ | 1 |
| Ariel, IM | 3 |
| Tubiana, M | 1 |
| Frindel, E | 1 |
| Vassort, F | 1 |
| McGinn, CJ | 1 |
| Kinsella, TJ | 2 |
| Pilliere, F | 1 |
| Levy, F | 1 |
| Renier, A | 1 |
| Brochard, P | 1 |
| Jaurand, MC | 1 |
| Donehower, RC | 1 |
| Lokich, J | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Zipoli, T | 1 |
| Moore, C | 1 |
| Gonsalves, L | 1 |
| Bagshawe, KD | 1 |
| Searle, F | 1 |
| Green, AJ | 1 |
| Begent, RH | 1 |
| Newlands, ES | 1 |
| Rustin, GJ | 1 |
| Adam, T | 1 |
| Albain, KS | 1 |
| Swinnen, LJ | 1 |
| Erickson, LC | 1 |
| Stiff, PJ | 1 |
| Fisher, RI | 1 |
| Froom, P | 1 |
| Aghai, E | 1 |
| Kinarty, A | 1 |
| Lahat, N | 1 |
| Ratain, MJ | 1 |
| Schilsky, RL | 1 |
| Wojack, BR | 1 |
| Simon, T | 1 |
| Senekjian, EK | 1 |
| Vogelzang, NJ | 1 |
| Raber, MN | 1 |
| Adams, F | 1 |
| Kavanagh, J | 1 |
| Legha, S | 1 |
| Dimery, I | 1 |
| Krakoff, I | 1 |
| Maynard, K | 1 |
| Parsons, PG | 1 |
| Schimke, RT | 1 |
| Hill, A | 1 |
| Johnston, RN | 1 |
| Sullivan, RD | 1 |
| Greenwald, ES | 1 |
| Simmonds, WP | 1 |
| Goffinet, DR | 1 |
| Bagshaw, MA | 1 |
| Alberto, P | 1 |
| Watne, AL | 1 |
| Elford, HL | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 1 |
| Mathé, G | 1 |
| Schneider, M | 1 |
| Jasmin, C | 1 |
| Hayat, M | 1 |
| Weiner, R | 1 |
| de Vassal, F | 1 |
| Amiel, JL | 1 |
| Beyer, HP | 1 |
| Fajbisowicz, S | 1 |
| Conroy, JF | 1 |
| Newbold, PC | 1 |
| Goldin, A | 1 |
| Zubrod, CG | 1 |
| Maruyama, Y | 1 |
| Lee, TC | 1 |
| Sullivan, S | 1 |
| Cooper, EH | 1 |
| Schuhmacher, J | 1 |
| Kampmann, H | 1 |
| Mattern, J | 1 |
| Volm, M | 2 |
| Wayss, K | 1 |
| Zimmerer, J | 1 |
| Lüscher, EF | 1 |
| Brunner, KW | 1 |
| Sartorelli, AC | 1 |
| Creasey, WA | 2 |
| Godwin, MC | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Capizzi, RL | 1 |
| DeConti, RC | 1 |
| Hussey, DH | 1 |
| Connors, TA | 1 |
| Kaufmann, K | 1 |
| Hinderer, H | 1 |
| Goerttler, K | 1 |
| Richards, GJ | 1 |
| Chambers, RG | 1 |
| Timson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 reviews available for hydroxyurea and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Mechanisms of Hydroxyurea-Induced Cellular Senescence: An Oxidative Stress Connection?
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Gene Expression Regulation, | 2021 |
Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; DNA Damage; Humans; Hydroxyurea; Mutation; Neopla | 2021 |
Underappreciated Roles of DNA Polymerase δ in Replication Stress Survival.
Topics: Animals; DNA Polymerase III; DNA Repair; DNA Replication; Humans; Hydroxyurea; Neoplasms; Oncogenes | 2021 |
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.
Topics: Animals; Antineoplastic Agents; Humans; Hydroxamic Acids; Hydroxyurea; Neoplasms | 2009 |
Hydroxyurea: a key player in cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Evaluation, | 2012 |
Mucocutaneous side effects of antineoplastic chemotherapy.
Topics: Alopecia; Antineoplastic Agents; Drug Eruptions; Hidradenitis; Humans; Hydroxyurea; Mucous Membrane; | 2004 |
[Cisplatin and derivatives with radiation therapy: for what clinical use?].
Topics: Animals; Anus Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Ph | 2004 |
[Molecular and cellular effects of hydroxyurea].
Topics: Animals; Cell Cycle; Cell Survival; Cells, Cultured; Cricetinae; DNA; Enzyme Inhibitors; Hydroxyurea | 1982 |
Use of hydroxyurea to alter drug resistance of human tumor cells.
Topics: Animals; Antineoplastic Agents; DNA; Drug Resistance; Gene Amplification; Humans; Hydroxyurea; Mice; | 1995 |
Hydroxyurea: new insights on an old drug.
Topics: Arthritis, Rheumatoid; Hematologic Diseases; Humans; Hydroxyurea; Neoplasms; Ribonucleotide Reductas | 1999 |
Other pharmaceutical agents.
Topics: Animals; Antineoplastic Agents; Antisickling Agents; Carcinogens; Cathartics; Disease Models, Animal | 2000 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra | 1992 |
An overview of the clinical experience with hydroxyurea.
Topics: Humans; Hydroxyurea; Neoplasms | 1992 |
Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers.
Topics: Cell Cycle; Chemotherapy, Adjuvant; Humans; Hydroxyurea; Neoplasms; Radiation-Sensitizing Agents; S | 1992 |
Cancer chemotherapy. II.
Topics: Animals; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Cytarabine; Dactinomycin; Dau | 1972 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Folic Acid A | 1970 |
Solid tumor chemotherapy: What have we to offer.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Dactinomycin; Floxuridine; Fluorouracil; Huma | 1970 |
Antimetabolites and psoriasis.
Topics: Adrenal Cortex Hormones; Animals; Antimetabolites; Arsenic; Humans; Hydroxyurea; Methotrexate; Mice; | 1972 |
Rationale of combination chemotherapy based on preclinical experiments.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma; Cytarabine; Drug Synergism; Humans; Hydroxyur | 1973 |
Present status of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Anti-Bacterial Agents; Antimetabolites; Carmustine; DNA, Neoplasm; Evalu | 1974 |
[Biochemical aspects of the therapy of advanced malignant tumors].
Topics: Adrenal Cortex Hormones; Alkaloids; Androgens; Anti-Bacterial Agents; Cyclophosphamide; DNA; DNA, Ne | 1966 |
[Progress in the drug therapy of cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cytarabine; Daunorubicin; Drug Syn | 1968 |
Cancer chemotherapy.
Topics: Alkaloids; Amides; Animals; Antineoplastic Agents; Asparaginase; Cell Division; Colchicine; Cytarabi | 1969 |
16 trials available for hydroxyurea and Benign Neoplasms
| Article | Year |
|---|---|
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Topics: Adolescent; Adult; Anemia, Sickle Cell; DNA Damage; Drug Utilization; Early Termination of Clinical | 2010 |
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; California; Chemi | 2002 |
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
Topics: Adult; Aged; Azacitidine; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Humans; | 1980 |
Modifiers of radiation response in tumor therapy: strategies and expectations.
Topics: Animals; Brachytherapy; Cell Line; Cell Survival; Clinical Trials as Topic; Cricetinae; Cricetulus; | 1982 |
Population pharmacokinetics of hydroxyurea in cancer patients.
Topics: Administration, Oral; Adult; Aged; Computer Simulation; Dose-Response Relationship, Drug; Female; Hu | 1995 |
A phase I trial of high-dose continuous-infusion hydroxyurea.
Topics: Adult; Aged; Bone Marrow Diseases; Female; Humans; Hydroxyurea; Infusions, Intravenous; Male; Middle | 1993 |
Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 1996 |
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Topics: Adult; Antineoplastic Agents; Drug Administration Schedule; Humans; Hydroxyurea; Infusions, Intraven | 1997 |
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Female; Half-Life; Humans; | 1998 |
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2001 |
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1991 |
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergis | 1988 |
Phase I trial of caracemide using bolus and infusion schedules.
Topics: Adult; Aged; Central Nervous System Diseases; Clinical Trials as Topic; Drug Administration Schedule | 1987 |
Hydroxyurea (NSC-32065) intermittent therapy in malignant diseases.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Hydroxyurea; Male; Middle Aged; Neoplasms | 1969 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
Topics: Adult; Aged; Blood Urea Nitrogen; Chondrosarcoma; Clinical Trials as Topic; Depression, Chemical; DN | 1970 |
92 other studies available for hydroxyurea and Benign Neoplasms
| Article | Year |
|---|---|
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
Topics: Carbonic Anhydrase Inhibitors; Cell Membrane; Cytosol; Humans; Hydroxamic Acids; Indicators and Reag | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Topics: Acetylation; Agaricales; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Humans; Hydro | 2016 |
Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm.
Topics: Humans; Hydroxyurea; Hypohidrosis; Myeloproliferative Disorders; Neoplasms | 2022 |
Replication stress generates distinctive landscapes of DNA copy number alterations and chromosome scale losses.
Topics: Aphidicolin; Chromatin; Chromosomal Instability; Chromosomes; DNA; DNA Copy Number Variations; Human | 2022 |
Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort.
Topics: Adult; Child; Cryopreservation; Fertility Preservation; Hematologic Diseases; Humans; Hydroxyurea; M | 2023 |
Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
Topics: Aspirin; Blood Platelets; Humans; Hydroxyurea; Myeloproliferative Disorders; Neoplasms | 2023 |
Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms.
Topics: Extracellular Traps; Humans; Hydroxyurea; Interferon alpha-2; Janus Kinase 2; Mutation; Myeloprolife | 2023 |
CaMKK2 and CHK1 phosphorylate human STN1 in response to replication stress to protect stalled forks from aberrant resection.
Topics: Calcium; DNA Replication; Genomic Instability; Humans; Hydroxyurea; Neoplasms | 2023 |
Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy.
Topics: Alternaria; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytarabine; Floxuridine; Glycosi | 2019 |
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Topics: Animals; Benzamides; Cell Plasticity; Cisplatin; DNA Repair; DNA Repair Enzymes; DNA-Binding Protein | 2020 |
Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology-oncology and transplant clinic: Assessment and significance.
Topics: Adolescent; Ambulatory Care; Antineoplastic Agents; beta-Thalassemia; Child; Child, Preschool; Femal | 2021 |
Targeting Neutrophils for Enhanced Cancer Theranostics.
Topics: Cell Line, Tumor; Drug Design; Drug Liberation; Humans; Hydroxyurea; Molecular Targeted Therapy; Nan | 2020 |
Replication catastrophe induced by cyclic hypoxia leads to increased APOBEC3B activity.
Topics: APOBEC Deaminases; Cell Hypoxia; Cell Line, Tumor; Cytidine Deaminase; Deamination; DNA Replication; | 2021 |
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms.
Topics: Animals; DNA Methylation; Hematopoiesis; Humans; Hydroxyurea; Mice; Neoplasms; Transcriptome | 2021 |
MOF Suppresses Replication Stress and Contributes to Resolution of Stalled Replication Forks.
Topics: Antineoplastic Agents; Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA Repair; DNA Replication; | 2018 |
Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy.
Topics: Anemia, Sickle Cell; Antineoplastic Agents, Alkylating; Case-Control Studies; Child; Child, Preschoo | 2018 |
Chemoresistance of cancer floating cells is independent of their ability to form 3D structures: Implications for anticancer drug screening.
Topics: Antibodies; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Adhesion; Cell Culture Techniques; | 2019 |
Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Topics: Animals; Antineoplastic Agents; Arginine; Disease Models, Animal; Doxorubicin; Female; Hydroxyurea; | 2018 |
Functionalized nitrogen doped graphene quantum dots and bimetallic Au/Ag core-shell decorated imprinted polymer for electrochemical sensing of anticancerous hydroxyurea.
Topics: Biosensing Techniques; Citric Acid; Electrochemical Techniques; Gold; Graphite; Humans; Hydroxyurea; | 2019 |
A cancer-associated point mutation disables the steric gate of human PrimPol.
Topics: Animals; Cell Cycle; Cell Line; Computer Simulation; DNA Primase; DNA-Directed DNA Polymerase; Drug | 2019 |
HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell | 2013 |
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, We | 2013 |
Reciprocal regulation of autophagy and dNTP pools in human cancer cells.
Topics: Animals; Autophagy; Gene Knockdown Techniques; Humans; Hydroxyurea; Intracellular Space; Mice, Inbre | 2014 |
QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors.
Topics: Enzyme Inhibitors; Flap Endonucleases; Humans; Hydroxyurea; Linear Models; Molecular Docking Simulat | 2015 |
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Replication; F | 2015 |
Differential and kinetic effects of cell cycle inhibitors on neoplastic and primary astrocytes.
Topics: Animals; Astrocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; DNA; Hydroxy | 2016 |
Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase.
Topics: Antineoplastic Agents; Binding Sites; Enzyme Inhibitors; Humans; Hydroxyurea; Molecular Docking Simu | 2016 |
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; | 2017 |
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; | 2009 |
The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2009 |
Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chromatin Immunoprecipitation; HCT116 Cells; HeLa Ce | 2009 |
HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy.
Topics: Antineoplastic Agents; AT-Hook Motifs; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-(Apurinic or Ap | 2009 |
Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after 1 year of follow-up.
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Female; Humans; Hydroxyurea; Male; Middle Aged; Na | 2009 |
Emergence of micronuclei and their effects on the fate of cells under replication stress.
Topics: Apoptosis; HeLa Cells; Humans; Hydroxyurea; Kinetics; Micronuclei, Chromosome-Defective; Microscopy; | 2010 |
Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications.
Topics: Anemia, Sickle Cell; Free Radicals; Gene Expression; HIV Infections; Humans; Hydroxyurea; Models, Th | 2011 |
Antiradical, chelating and antioxidant activities of hydroxamic acids and hydroxyureas.
Topics: Anemia, Sickle Cell; beta Carotene; Biphenyl Compounds; Butylated Hydroxyanisole; Butylated Hydroxyt | 2011 |
Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Cycle; Culture Media, Serum-Free; DNA; En | 2002 |
Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
Topics: Adenine; Adenylyl Cyclases; Anti-HIV Agents; Cell Division; Cyclooxygenase Inhibitors; Humans; Hydro | 2003 |
CYTOTOXICITY OF HYDROXYUREA (NSC-32065) REVERSIBLE BY PYRIMIDINE DEOXYRIBOSIDES IN A MAMMALIAN CELL LINE GROWN IN VITRO.
Topics: Antimetabolites; Cell Line; Cricetinae; Hydroxyurea; In Vitro Techniques; Neoplasms; Neoplasms, Expe | 1964 |
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN.
Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi | 1964 |
ERYTHEMA IN AREAS OF PREVIOUS IRRADIATION IN PATIENTS TREATED WITH HYDROXYUREA (NSC-32065).
Topics: Antineoplastic Agents; Drug Therapy; Erythema; Hydroxyurea; Neoplasms; Radiation Injuries; Toxicolog | 1964 |
PEDIATRIC CLINICAL TRIALS WITH HYDROXYUREA (NSC-32065).
Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Neop | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MISCELLANEOUS TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Carcinom | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CANCER OF THE BREAST.
Topics: Anemia; Anemia, Myelophthisic; Antineoplastic Agents; Breast Neoplasms; Drug Therapy; Erythema; Estr | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: UROLOGIC AND GYNECOLOGIC NEOPLASMS.
Topics: Adenocarcinoma; Anemia; Anemia, Aplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Ther | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukopenia; Lymphoma; Lymphoma, L | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CLINICAL EVALUATION.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leu | 1964 |
HYDROXYUREA ADMINISTERED INTERMITTENTLY.
Topics: Antineoplastic Agents; Drug Therapy; Geriatrics; Hydroxyurea; Neoplasms; Toxicology; Urea | 1965 |
CLINICAL RESULTS WITH HYDROXYUREA IN CANCER CHEMOTHERAPY; PRELIMINARY REPORT.
Topics: Antineoplastic Agents; Biomedical Research; Hydroxyurea; Neoplasms; Pharmacology; Toxicology | 1965 |
Turning immunological memory into amnesia by depletion of dividing T cells.
Topics: Animals; Cell Division; Female; Flow Cytometry; Ganciclovir; Hyaluronan Receptors; Hydroxyurea; Immu | 2003 |
Malignancy in patients with sickle cell disease.
Topics: Adolescent; Adult; Age of Onset; Anemia, Sickle Cell; Child; Child, Preschool; Data Collection; Huma | 2003 |
Synthesis and NMR characterization of hydroxyurea and mesylglycol glycoconjugates as drug candidates for targeted cancer chemotherapy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Glycoconjugates; Hydroxyurea; Magnetic Resonance Spect | 2005 |
Treatment with hydroxyurea and tyrphostin-1 significantly improves the transduction efficiency of recombinant adeno-associated viruses in human cancer cells.
Topics: Adenoviridae; beta-Galactosidase; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; DNA, Recom | 2005 |
Hydroxyurea in the management of head and neck cancer. II. Surgical aspects.
Topics: Antineoplastic Agents; Head; Head and Neck Neoplasms; Humans; Hydroxyurea; Mandibular Neoplasms; Neo | 1967 |
Higher leukocyte nadirs with lithium carbonate after chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Humans; Hydroxyure | 1980 |
Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro.
Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxo | 1983 |
Cancer chemotherapy: those dreaded side effects and what to do about them. Part five.
Topics: Antineoplastic Agents; Asparaginase; Cisplatin; Dacarbazine; Humans; Hydroxyurea; Neoplasms; Procarb | 1981 |
Hydroxyurea revisited: a decade of clinical effects studies.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Cricetinae; Cricetulus; Evaluation Studies a | 1981 |
Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization.
Topics: Administration, Oral; Bone Marrow; Drug Administration Schedule; Half-Life; Humans; Hydroxyurea; Inf | 1980 |
New assay for the rapid determination of plasma holotranscobalamin II levels: preliminary evaluation in cancer patients.
Topics: Adsorption; Chromatography; Glass; Hematologic Tests; Homocysteine; Humans; Hydroxyurea; Microsphere | 1993 |
The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Biopsy, | 1993 |
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Topics: Antineoplastic Agents; Blood Platelets; Clinical Trials as Topic; Colonic Neoplasms; Endothelial Gro | 1997 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Int | 2001 |
Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell | 2000 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies: a preliminary report.
Topics: Adult; Bleomycin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Therapy, Combination; | 1976 |
Systemic chemotherapy for psoriasis: a national survey.
Topics: Adult; Azauridine; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Utiliz | 1976 |
Investigations on pharmacologic induction of partial synchronization of tumor cell proliferation: its relevance for cytostatic therapy.
Topics: Adolescent; Adult; Aged; Animals; Carcinoma, Ehrlich Tumor; Cell Division; Cyclophosphamide; Drug Ad | 1976 |
Treatment of disseminated cancer by intravenous hydroxyurea and autogenous bone-marrow transplants: experience with 35 patients.
Topics: Bone Marrow Cells; Bone Marrow Transplantation; Hematopoietic System; Humans; Hydroxyurea; Injection | 1975 |
Critical survey of experimental data on in vivo synchronization by hydroxyurea.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Clone Cells; DNA, Neoplasm; H | 1975 |
Induction of DNA-repair synthesis (UDS) in rat pleural mesothelial cells by urine of subjects exposed to genotoxic agents.
Topics: Adult; Animals; Cells, Cultured; Chromium; DNA Repair; DNA Replication; Epithelium; Humans; Hydroxyu | 1992 |
In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.
Topics: Administration, Oral; Adult; Aged; Deoxyuridine; DNA; Female; Gamma Cameras; Humans; Hydroxyurea; Id | 1991 |
Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; DNA Repair; Drug | 1990 |
Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Topics: Bloodletting; Humans; Hydroxyurea; Interferon Type I; Interleukin-2; Killer Cells, Natural; Myelopro | 1989 |
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Topics: Adenoviridae; Alkylating Agents; Cell Line; Cell Survival; Dacarbazine; Drug Resistance; Humans; Hyd | 1986 |
Fifth Gordon Hamilton-Fairley memorial lecture. Methotrexate resistance and gene amplification: an experimental model for the generation of cellular heterogeneity.
Topics: Animals; Cells, Cultured; Chromosome Aberrations; DNA; DNA Replication; Drug Resistance; Gene Amplif | 1985 |
Chemotherapy in head and neck cancer.
Topics: Administration, Oral; Antineoplastic Agents; Arteries; Carcinoma, Squamous Cell; Head; Head and Neck | 1971 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Effect of hydroxyurea on ribonucleotide reductase.
Topics: Animals; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Chick Embryo; Cytosine Nucleotide | 1968 |
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D | 1972 |
Cancer chemotherapy: mechanisms of action.
Topics: Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Binding Sites; Cyt | 1973 |
Age cohort variation of tumor cells.
Topics: Animals; Cell Division; Disease Models, Animal; DNA, Neoplasm; Fluorouracil; Hydroxyurea; Lymphoma; | 1973 |
The effects of chemotherapy on the morphology of solid tumours.
Topics: Antineoplastic Agents; Cell Division; Cell Nucleus; Cells; Cytarabine; Hydroxyurea; Intestinal Mucos | 1974 |
Anticancer therapy with hydrea: comparative study of daily vs. intermittent oral dosage.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Dr | 1974 |
Incorporation of 131 iododeoxyuridine into the DNA of tumour-bearing rats after partial synchronization as a tool in scintigraphic tumour localization.
Topics: Animals; Cell Division; DNA; DNA, Neoplasm; Hydroxyurea; Iodine Radioisotopes; Male; Neoplasm Transp | 1974 |
Combined hydroxyurea and radiotherapy: a new dosage schedule.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms; | 1972 |
An outline of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Asparaginase; Breast Neoplasms; | 1971 |
Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors.
Topics: Ambulatory Care; Hematopoiesis; Humans; Hydroxyurea; Neoplasms; Organ Specificity | 1970 |
[Quick method for sensitivity tests of malignant tumors against antineoplastic agents].
Topics: DNA; Hydroxyurea; Neoplasms; Thymidine; Tritium | 1970 |
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck.
Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo | 1969 |
Hydroxyurea: comparison of cytotoxic and antimitotic activities against human lymphocytes in vitro.
Topics: Culture Techniques; Humans; Hydroxyurea; Lectins; Lymphocytes; Mitosis; Neoplasms | 1969 |